References
- SollingerHWMycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study GroupTransplantation19956032252327645033
- ArnsWBreuerSChoudhurySEnteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophe-nolate mofetilClin Transplant200519219920615740555
- StaatzCETettSEClinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipientsClin Pharmacokinet2007461135817201457
- YangJWLeePHHutchinsonIVPravicaVShahTMinDIGenetic polymorphisms of MRP2 and UGT2B7 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acidTher Drug Monit200931554254819730281
- BetônicoGNAbbud-FilhoMGoloni-BertolloEMInfluence of UDP-glucuronosyltransferase polymorphisms on mycophenolate mofetil-induced side effects in kidney transplant patientsTransplant Proc200840370871018454993
- SuhailSMVathsalaALouHXWooKTSafety and efficacy of mycophenolate mofetil for prophylaxis in Asian renal transplant recipientsTransplant Proc20003271757175811119922
- ZhouPJXuDYuZCWangXHShaoKZhaoJPPharmacokinetics of mycophenolic acid and estimation of exposure using multiple linear regression equations in Chinese renal allograft recipientsClin Pharmacokinet200746538940117465638
- KrämerBKDel CastilloDMargreiterREuropean Tacrolimus versus Ciclosporin Microemulsion Renal Transplantation Study GroupEfficacy and safety of tacrolimus compared with ciclosporin A in renal transplantation: three-year observational resultsNephrol Dial Transplant20082372386239218258740
- JirasirithamSSumethkulVMavichakVNa-BangchangKThe pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipientsTransplant Proc20043672076207815518751
- van GelderTDomkeIEngelmayerJClinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS methodTher Drug Monit200931221822319214147
- CarterKWMcCaskiePAPalmerLJJLIN: a java based linkage disequilibrium plotterBMC Bioinformatics200676016466584
- TakahashiKUchidaKYoshimuraNEfficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients: 12-month resultsTransplant Res2013211423866828
- KuypersDRClaesKEvenepoelPLong-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipientsJ Clin Pharmacol200343886688012953344
- FigurskiMJPawińskiTGoldbergLRPharmacokinetic monitoring of mycophenolic acid in heart transplant patients: correlation the side-effects and rejections with pharmacokinetic parametersAnn Transplant2012171687822466911
- MouradMMalaiseJChaib EddourDCorrelation of myco-phenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetilClin Chem2001471889411148182
- KnightSRMorrisPJDoes the evidence support the use of myco-phenolate mofetil therapeutic drug monitoring in clinical practice? A systematic reviewTransplantation200885121675168518580456
- YauWPVathsalaALouHXChanEIs a standard fixed dose of mycophenolate mofetil ideal for all patients?Nephrol Dial Transplant200722123638364517640939
- BernardOTojcicJJournaultKPerusseLGuillemetteCInfluence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acidDrug Metab Dispos20063491539154516790554
- KagayaHInoueKMiuraMInfluence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipientsEur J Clin Pharmacol200763327928817211619
- LévesqueEDelageRBenoit-BiancamanoMOThe impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteersClin Pharmacol Ther200781339240017339869
- DuguayYBáárCSkorpenFGuillemetteCA novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activityClin Pharmacol Ther200475322323315001974
- MiuraMSatohSInoueKInfluence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacoki-netics in Japanese renal transplant recipientsEur J Clin Pharmacol200763121161116917906856
- GuoDPangLFHanYPolymorphisms of UGT1A9 and UGT2B7 influence the pharmacokinetics of mycophenolic acid after a single oral dose in healthy Chinese volunteersEur J Clin Pharmacol201369484384923052409